Ambalal Sarabhai Enterprises is locked its upper circuit limit at Rs. 31.00, up by 1.45 points or 4.91% from its previous closing of Rs. 29.55 on the BSE.
The scrip opened at Rs. 31.00 and has touched a high and low of Rs. 31.00 and Rs. 31.00 respectively. So far 143776 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 65.00 on 28-May-2021 and a 52 week low of Rs. 16.55 on 25-Sep-2020.
Last one week high and low of the scrip stood at Rs. 30.20 and Rs. 28.40 respectively. The current market cap of the company is Rs. 237.56 crore.
The promoters holding in the company stood at 30.76%, while Non-Institutions held 69.24%.
CoSara Diagnostics, a Joint Venture (JV) of a subsidiary of Ambalal Sarabhai Enterprises and Co-Diagnostics, Inc, has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell SARAGENE Dengue Test Kit. The tests are now available for sale.
SARAGENE Dengue Test Kit is an in vitro diagnostic test, based on Real-Time Polymerase Chain Reaction Technology. Test utilizes Co-Diagnostics' patented CoPrimers technology (Satterfield, 2014) (Poritz & Ririe, 2014). It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1688.75 |
Dr. Reddys Lab | 1108.55 |
Cipla | 1433.45 |
Lupin | 1982.65 |
Zydus Lifesciences | 859.55 |
View more.. |